Exploiting multiple hit-identification strategies to identify novel inhibitors of the anti-infective target DXPS
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Saarbrücken, Universität des Saarlandes, Dissertation, 2022
- Event
-
Veröffentlichung
- (where)
-
Saarbrücken
- (who)
-
Saarländische Universitäts- und Landesbibliothek
- (when)
-
2022
- Creator
-
Johannsen, Sandra
- Contributor
-
Hirsch, Anna K. H.
- DOI
-
10.22028/D291-37477
- URN
-
urn:nbn:de:bsz:291--ds-374775
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:50 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Johannsen, Sandra
- Hirsch, Anna K. H.
- Saarländische Universitäts- und Landesbibliothek
Time of origin
- 2022
Other Objects (12)
Altes Target, Neue Hits - Entwicklung von Inhibitoren für die PIM1-Kinase
Predicting and Exploiting the Determinants of Protein/Protein Interactions to Identify Low-Molecular Inhibitors of RUNX1-ETO Tetramerization
Exploiting background knowledge on evolving objects to identify relevant dimensions for classification
Targets and Off-Targets of Kinase Inhibitors in Diabetes
Exploiting the ubiquitin system to identify novel vulnerabilities in B-cell malignancies and lung adenocarcinoma
Targets missed: three case studies exploiting the linked SHARE-RV data
RNAi screen in primary AML cells to identify new therapeutic targets
Target gene regulation by EBV latent transcription factors - exploiting cellular enhancer elements
Pharmacological plasticity - how do you hit a moving target?
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets
Altes Target, Neue Hits - Entwicklung von Inhibitoren für die PIM1-Kinase
Predicting and Exploiting the Determinants of Protein/Protein Interactions to Identify Low-Molecular Inhibitors of RUNX1-ETO Tetramerization
Exploiting background knowledge on evolving objects to identify relevant dimensions for classification
Targets and Off-Targets of Kinase Inhibitors in Diabetes
Exploiting the ubiquitin system to identify novel vulnerabilities in B-cell malignancies and lung adenocarcinoma
Targets missed: three case studies exploiting the linked SHARE-RV data
RNAi screen in primary AML cells to identify new therapeutic targets
Target gene regulation by EBV latent transcription factors - exploiting cellular enhancer elements
Pharmacological plasticity - how do you hit a moving target?
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets
Altes Target, Neue Hits - Entwicklung von Inhibitoren für die PIM1-Kinase
Predicting and Exploiting the Determinants of Protein/Protein Interactions to Identify Low-Molecular Inhibitors of RUNX1-ETO Tetramerization
Exploiting background knowledge on evolving objects to identify relevant dimensions for classification
Targets and Off-Targets of Kinase Inhibitors in Diabetes
Exploiting the ubiquitin system to identify novel vulnerabilities in B-cell malignancies and lung adenocarcinoma
Targets missed: three case studies exploiting the linked SHARE-RV data
RNAi screen in primary AML cells to identify new therapeutic targets
Target gene regulation by EBV latent transcription factors - exploiting cellular enhancer elements
Pharmacological plasticity - how do you hit a moving target?
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]
Neue Strukturen und Targets für β-Laktamase-Inhibitoren [Beta-Laktamase-Inhibitoren]